VANCOUVER, British Columbia, Jan. 25, 2018 -
Please note this is an Official Company News Release.
Breathtec Biomedical Inc. (CSE:BTH)
(CNSX:BTH)
(FRANKFURT:BTI) (OTCQB:BTHCF)
(the “Company”) is pleased to report on the development of its
Breathtec Disease Detection Breathalyzer (“V2”) prototype based on
the FAIMS (field asymmetric waveform ion mobility spectrometry)
technology. In collaboration with Cannabix Technologies (CSE:BLO), the V2
prototype is now complete. The new device, classified as “V3” is designed
to operate both independently with its own self-contained FAIMS detector,
or coupled in tandem directly to a triple-quadrupole Mass Spectrometer
(MS) device. The device also incorporates several technological
enhancements, including a modular design for faster iterative development,
as well as size reduction into a compact Point-of-Care (POC) design.
Preliminary bench testing indicates a direct correlation between the V3
device and the MS. The MS is considered the gold standard in biomarker
detection and it is anticipated that any results from a breathalyzer for
disease detection will have to be independently verified by MS.
The Company plans to further develop the V3 device and implement findings
from ongoing research conducted on biomarkers found in the breath that are
associated with diseases, and continue on the path of developing hand-held
Breathtec Disease Detection Breathalyzers to be non-invasive and highly
accurate detection methods for various diseases.
CTO Mike Costanzo states, “Breathtec Biomedical remains dedicated to the
development of a highly sensitive breathalyzer for disease detection. With
our collaboration with Cannabix and the Vancouver Technical Team, we can
expedite the testing and analysis of biomarkers related to disease.”
Update on Management
Breathtec Biomedical is currently in advanced talks with candidates for
CEO to lead Breathtec Biomedical and will make announcements as the
company progresses in its evaluation of candidates.
ON BEHALF OF THE BOARD
“Michael Sadhra”
Chief Financial Officer & Director
ABOUT BREATHTEC BIOMEDICAL INC.
Breathtec Biomedical, Inc. (“Breathtec”) was formed to propel innovative
research in the area of airborne analysis as a medical screening tool. Our
efforts are aimed at leading the development of commercially viable
methods for the early screening of certain pathogens. Our primary avenue
of investigation is focused on innovation and advances in the field of
specialized mass spectrometry. For more information, visit www.breathtecbiomedical.com.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor
accepts responsibility for the adequacy or accuracy of the content of
this news release. This news release contains forward-looking statements
relating to product development, licensing, commercialization and
regulatory compliance issues and other statements that are not
historical facts. Forward-looking statements are often identified by
terms such as “will”, “may”, “should”, “anticipate”, “expects” and
similar expressions. All statements other than statements of historical
fact, included in this release are forward-looking statements that
involve risks and uncertainties. There can be no assurance that such
statements will prove to be accurate and actual results and future
events could differ materially from those anticipated in such
statements. Important factors that could cause actual results to differ
materially from the Company’s expectations include the failure to
satisfy the conditions of the relevant securities exchange(s) and other
risks detailed from time to time in the filings made by the Company with
securities regulations. The reader is cautioned that assumptions used in
the preparation of any forward-looking information may prove to be
incorrect. Events or circumstances may cause actual results to differ
materially from those predicted, as a result of numerous known and
unknown risks, uncertainties, and other factors, many of which are
beyond the control of the Company. The reader is cautioned not to place
undue reliance on any forward-looking information. Such information,
although considered reasonable by management at the time of preparation,
may prove to be incorrect and actual results may differ materially from
those anticipated. Forward-looking statements contained in this news
release are expressly qualified by this cautionary statement. The
forward-looking statements contained in this news release are made as of
the date of this news release and the Company will update or revise
publicly any of the included forward-looking statements as expressly
required by applicable law.
CONTACT:
Alfred Wong
Tel: 604 398 8840 ext 700
info@breathtechbiomedical.com
investors@breathtecbiomedical.com